StockData

Veracyte vs GeneDx

VCYT and WGS side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How VCYT and WGS compare

Veracyte is the larger company, worth 1.3 times as much as GeneDx ($1.9B against $1.5B).

GeneDx grew revenue faster over the last twelve months (25.4% versus 17.3% for Veracyte).

Veracyte keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −23.4% at GeneDx.

Veracyte scores higher on the StockData Score (16 against 6 for GeneDx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricVCYTWGS
Size and price
Market cap$1.9B$1.5B
Share price$24.23$51.02
Change, 1 year−38.4%−60.9%
Change, 5 years−41.7%−77.6%
Beta (5Y)1.920.82
Employees7551,300
StockData Score
Total score16 (better)6
Valuation score4 (better)0
Growth score33
Performance score3 (better)1
Health score6 (better)2
Dividend score00
Valuation
P/E17.3×–
P/S3.5×3.3× (better)
P/B1.4× (better)6.2×
EV/EBITDA13.0×–
P/FCF11.7×–
FCF yield8.5% (better)−5.0%
Fair value$36.51$32.23
Margin of safety33.6% (better)−58.3%
Growth
Revenue growth (TTM)17.3%25.4% (better)
Revenue growth, 5Y average34.5% (better)19.0%
Net income growth (TTM)335% (better)−7665%
EPS growth (TTM)324% (better)−18300%
Profitability
Gross margin71.7% (better)69.4%
Operating margin18.8% (better)−20.3%
Net margin20.4% (better)−23.4%
FCF margin29.5% (better)−16.7%
Return on equity8.8% (better)−40.8%
Return on invested capital10.0% (better)−36.2%
Financial health
Debt / equity0.000.40 (better)
Current ratio9.16 (better)3.30
Altman Z-score12.65 (better)0.36
Piotroski F-score7 (better)6
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions111%107%
Held by insiders1.7%–
Insider net buying, 12 months−$18.6M$91.2M (better)
Short interest, % of float12.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.